Free Trial
→ Alert: Prepare for Trump's Dollar Overhaul (From Brownstone Research) (Ad)tc pixel Free IPHYF Stock Alerts

Innate Pharma (IPHYF) SEC Filings & 10K Form

Innate Pharma logo
$2.00 0.00 (0.00%)
As of 09/16/2025
Compare

Recent Innate Pharma SEC Filings

Export to Excel
DateFilerForm TypeView
09/17/2025
5:40 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/17/2025
5:24 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/15/2025
5:00 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/10/2025
5:06 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/02/2025
7:52 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/04/2025
5:49 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/29/2025
5:24 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/07/2025
5:03 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/17/2025
5:05 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/13/2025
5:00 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/30/2025
7:31 AM		Innate Pharma (Subject)
Innate Pharma SA (Subject)
NOVO NORDISK A S (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/27/2025
5:03 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/23/2025
5:11 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/23/2025
5:17 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/19/2025
5:03 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/15/2025
5:00 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/13/2025
5:03 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/12/2025
5:03 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/06/2025
5:01 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/30/2025
10:31 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/30/2025
8:01 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 20-F
Registration statement / Annual report / Transition report  
04/29/2025
5:48 PM		Innate Pharma (Subject)
Innate Pharma SA (Subject)
Sanofi (Filed by)
Sanofi (Filed by)
Form SCHEDULE 13G/A
04/29/2025
2:02 PM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/28/2025
5:00 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/24/2025
5:03 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/23/2025
7:28 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/16/2025
5:05 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/16/2025
5:07 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/03/2025
5:00 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/27/2025
6:01 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/26/2025
6:07 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/25/2025
6:23 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/20/2025
6:24 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/27/2025
5:01 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/18/2025
5:16 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/27/2025
6:57 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/21/2025
5:00 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/16/2025
7:16 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/10/2025
5:01 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/20/2024
6:03 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/09/2024
5:04 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/06/2024
5:00 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/03/2024
5:03 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/20/2024
5:02 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/19/2024
5:01 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/13/2024
5:00 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/08/2024
5:00 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/07/2024
5:00 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/29/2024
6:03 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/15/2024
5:11 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/30/2024
5:15 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/23/2024
5:03 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
(Data available from 1/1/2016 forward)


Related Companies and Tools

Related Companies
SEC Filings Tools

This page (OTCMKTS:IPHYF) was last updated on 9/19/2025 by MarketBeat.com Staff
From Our Partners
He Called Nvidia at $1.10. Now, He Says THIS Stock Will…
The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...
The Oxford Club | Sponsoredtc pixel
A New Way to Double Your Retirement Income?
Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...
Investors Alley | Sponsoredtc pixel
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsoredtc pixel
Strange crypto pattern discovered by 40-person research team
Something unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...
Crypto Swap Profits | Sponsoredtc pixel
Trump's Law S.1582: $21T Dollar Revolution Coming
Do you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...
Brownstone Research | Sponsoredtc pixel
“Fed Proof” Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank ac...
Weiss Ratings | Sponsoredtc pixel
Forget NVDA. Put $1,000 into this stock now
A massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...
Chaikin Analytics | Sponsoredtc pixel
Prepare for the “Mar-a-Lago Accord” Money Shock
Why Are Wall Street Insiders Moving Their Money to This ONE Asset? Something far more consequential for you...
Stansberry Research | Sponsoredtc pixel